Watch these video interviews on the iPad edition of this issue by OT reporter Peter Goodwin:
Metastatic Colorectal Cancer: Extended-RAS, Rather than K-RAS, Mutations Predict Anti-EGFR Efficacy Better
Marc Peeters, MD, PhD: The choice of whether to accompany chemotherapy for metastatic colorectal cancer with a vascular endothelial growth factor (VEG-F) receptor inhibitor such as bevacizumab or an anti-epidermal growth factor receptor (EGFR) monoclonal antibody such as cetuximab or panitumumab was made clearer by research reported at the meeting. The criterion for excluding EGFR-inhibition was found to be mutation of any gene in the RAS extended family, not just mutated KRAS. Peeters discusses the details of his group's findings from the first-line PRIME study of survival outcomes in patients with KRAS/NRAS (RAS) wild-type metastatic colorectal cancer and the second-line 20050181 study of KRAS/NRAS and BRAF mutations in patients treated with panitumumab plus FOLFIRI (Abstract 3557 and Abstract 3568).
CLL: Ibrutinib Delays Progression, Extends Survival for Patients with Refractory/Relapsing Disease
John Byrd, MD, elaborates on the Phase III RESONATE trial he reported, showing that patients with relapsing or refractory chronic lymphocytic leukemia lived longer and had markedly delayed progression of their disease when randomized to treatment with the Bruton's tyrosine kinase inhibitor ibrutinib rather than the current standard therapy of ofatumumab-irrespective of their deletion 17p status (Abstract LBA7008, OT 7/25/14 issue).
If you are not yet receiving our iPad issues, download the free Oncology Times app from the App Store today! Visithttp://bit.ly/OT-iPadApp, search in the App Store, or follow the link onhttp://oncology-times.com.